Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.61 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.43 |
| ▸ | NQO2 | P16083 | 4/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095554 | 0.91 | ESR1 (0.61) | ESR1ESR2ABHD6DRD1HSD11B1 | |
| SCHEMBL1094365 | 0.87 | ESR1 (0.47) | ESR1ESR2ABHD6DRD1KDM4E | |
| SCHEMBL14480254 | 0.86 | MTNR1B (0.50) | ESR1ESR2DRD1KDM4EALDH1A1 | |
| SCHEMBL1095538 | 0.85 | ESR1 (0.65) | ESR1ESR2ABHD6DRD1HSD11B1 | |
| SCHEMBL4937667 | 0.85 | ESR1 (0.65) | ESR1ESR2ABHD6DRD1HSD11B1 | |
| SCHEMBL4551326 | 0.84 | ESR1 (0.53) | ESR1ESR2ABHD6HSD11B1KDM4E | |
| SCHEMBL1094619 | 0.83 | ESR1 (0.62) | ESR1ESR2ABHD6DRD1HSD11B1 | |
| SCHEMBL1095164 | 0.82 | ESR1 (0.61) | ESR1ESR2ABHD6DRD1HSD11B1 | |
| SCHEMBL6656989 | 0.81 | ESR1 (0.60) | ESR1ESR2ABHD6DRD1HSD11B1 | |
| SCHEMBL1095476 | 0.81 | MTNR1B (0.43) | ESR1ESR2DRD1LMNAMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2374796-B1 | 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorderes | ARENA PHARM INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160250223-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2016-09-01 | — | — | US | disclosed |
| US-20160024014-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-8993750-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150087634-A1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS | ARENA PHARMACEUTICALS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-20150045552-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8846906-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8575149-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8546378-B2 | 5HT2C receptor modulator compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130217676-A1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-08-22 | — | — | US | disclosed |
| US-7514422-B2 | 5HT2c receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1833473-A2 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE | Arena Pharmaceuticals, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070060568-A1 | Obesity therapy; using 3-benzoazepine compound | ARENA PHARMACEUTICALS, A DELAWARE CORPORATION | 2007-03-15 | — | — | US | disclosed |
| EP-1411881-B9 | 5HT2C RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2006071740-A2 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-06 | — | — | WO | disclosed |
| US-6953787-B2 | 5HT2C receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| EP-1557409-A1 | 5HT2C receptor modulators | Arena Pharmaceuticals, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1411881-B1 | 5HT2C RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2005-05-04 | — | — | EP | disclosed |
| US-20050020573-A1 | Obesity; using 3-benoazepine compound | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | US | disclosed |
| US-20030225057-A1 | 3-Benzoazepine derivatives | ARENA PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225057-A1 | 3-Benzoazepine derivatives | HTR2C, HTR1A, HTR3A | ESR1 1510/4885ESR2 848/4885ABHD6 1065/4885 |
| US-20050020573-A1 | Obesity; using 3-benoazepine compound | HTR2C, HTR3C, HTR3B | ESR1 2872/4885ESR2 1307/4885ABHD6 893/4885 |
| US-20070060568-A1 | Obesity therapy; using 3-benzoazepine compound | HTR2C, HTR3B, HTR3C | ESR1 1112/4885ESR2 733/4885ABHD6 891/4885 |
| US-20130217676-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | ESR1 1469/4885ESR2 559/4885ABHD6 927/4885 |
| US-20150087634-A1 | 5HT2C RECEPTOR MODULATOR COMPOSITIONS | HTR2C, HTR2A, HTR5A | ESR1 1578/4885ESR2 1476/4885ABHD6 1303/4885 |
| US-20160024014-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | ESR1 1469/4885ESR2 559/4885ABHD6 927/4885 |
| US-20150045552-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | ESR1 1469/4885ESR2 559/4885ABHD6 927/4885 |
| US-20160250223-A1 | 5HT2C RECEPTOR MODULATORS | HTR2C, HTR2A, HTR1A | ESR1 1469/4885ESR2 559/4885ABHD6 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.